265 related articles for article (PubMed ID: 35714477)
1. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Tombal B; Sternberg CN; Hussain M; Ganguli A; Li Y; Sandin R; Bhadauria H; Oh M; Saad F
ESMO Open; 2022 Jun; 7(3):100510. PubMed ID: 35714477
[TBL] [Abstract][Full Text] [Related]
2. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
[TBL] [Abstract][Full Text] [Related]
3. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Lefebvre P; McQuarrie K; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2020 Jan; 37(1):512-526. PubMed ID: 31813087
[TBL] [Abstract][Full Text] [Related]
4. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
[TBL] [Abstract][Full Text] [Related]
5. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
Chowdhury S; Oudard S; Uemura H; Joniau S; Dearden L; Capone C; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2022 Jan; 39(1):518-531. PubMed ID: 34797506
[TBL] [Abstract][Full Text] [Related]
6. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.
Shore N; Jiang S; Garcia-Horton V; Terasawa E; Steffen D; Chin A; Ayyagari R; Partridge J; Waldeck AR
Adv Ther; 2022 Nov; 39(11):5025-5042. PubMed ID: 36028656
[TBL] [Abstract][Full Text] [Related]
7. Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.
Wallis CJD; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z
Eur Urol Oncol; 2018 Aug; 1(3):238-241. PubMed ID: 31102627
[TBL] [Abstract][Full Text] [Related]
8. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
[TBL] [Abstract][Full Text] [Related]
9. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
[TBL] [Abstract][Full Text] [Related]
10. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Wenzel M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Tilki D; Graefen M; Kluth LA; Briganti A; Mandel P; Montorsi F; Chun FKH; Karakiewicz PI
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):139-148. PubMed ID: 34054128
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada.
Saad F; Chilelli A; Hui B; Muratov S; Ganguli A; North S; Shayegan B
J Med Econ; 2022; 25(1):583-590. PubMed ID: 35469527
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
[TBL] [Abstract][Full Text] [Related]
14. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
[TBL] [Abstract][Full Text] [Related]
15. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
Feng FY; Thomas S; Saad F; Gormley M; Yu MK; Ricci DS; Rooney B; Brookman-May S; McCarthy S; Olmos D; Chowdhury S; Hadaschik B; Liu Y; Davicioni E; Smith MR; Small EJ
JAMA Oncol; 2021 Jul; 7(7):1005-1014. PubMed ID: 34081076
[TBL] [Abstract][Full Text] [Related]
16. Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis.
Roumiguié M; Paoletti X; Neuzillet Y; Mathieu R; Vincendeau S; Kleinclauss F; Mejean A; Guy L; Timsit MO; Lebret T
Future Oncol; 2021 May; 17(14):1811-1823. PubMed ID: 33543650
[No Abstract] [Full Text] [Related]
17. Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis.
Wang L; Paller C; Hong H; Rosman L; De Felice A; Brawley O; Alexander GC
J Natl Cancer Inst; 2022 Feb; 114(2):191-202. PubMed ID: 33830214
[TBL] [Abstract][Full Text] [Related]
18. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
Saad F; Small EJ; Feng FY; Graff JN; Olmos D; Hadaschik BA; Oudard S; Londhe A; Bhaumik A; Lopez-Gitlitz A; Thomas S; Mundle SD; Chowdhury S; Smith MR
Eur Urol; 2022 Feb; 81(2):184-192. PubMed ID: 34916086
[TBL] [Abstract][Full Text] [Related]
19. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of enzalutamide and apalutamide in the treatment of non-metastasic castration-resistant prostate cancer: Indirect comparison.
Nieto-Gómez P; Ubago-Pérez R; Cabeza-Barrera J
Actas Urol Esp (Engl Ed); 2019 Sep; 43(7):355-363. PubMed ID: 31133348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
